2025
Society for Immunotherapy of Cancer: updates and best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) image analysis and data sharing
Taube J, Sunshine J, Angelo M, Akturk G, Eminizer M, Engle L, Ferreira C, Gnjatic S, Green B, Greenbaum S, Greenwald N, Hedvat C, Hollmann T, Jiménez-Sánchez D, Korski K, Lako A, Parra E, Rebelatto M, Rimm D, Rodig S, Rodriguez-Canales J, Roskes J, Schalper K, Schenck E, Steele K, Surace M, Szalay A, Tetzlaff M, Wistuba I, Yearley J, Bifulco C. Society for Immunotherapy of Cancer: updates and best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) image analysis and data sharing. Journal For ImmunoTherapy Of Cancer 2025, 13: e008875. PMID: 39779210, PMCID: PMC11749220, DOI: 10.1136/jitc-2024-008875.Peer-Reviewed Original ResearchConceptsSociety for ImmunotherapyMultiplex immunohistochemistrySociety for Immunotherapy of CancerImmunotherapy of cancerImmune cell subsetsPractice guidelinesCell subsetsTumor microenvironmentGeneration of robust dataTask ForceComplex immunophenotypeAcademic centersMarker expressionMIHC/IFClinical useClinical implementationImmunohistochemistryQuantitative image analysisImmunofluorescenceDiagnostic companiesRobust dataAssayImage analysisManagement considerationsStaining protocol
2021
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
Doroshow DB, Bhalla S, Beasley MB, Sholl LM, Kerr KM, Gnjatic S, Wistuba II, Rimm DL, Tsao MS, Hirsch FR. PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nature Reviews Clinical Oncology 2021, 18: 345-362. PMID: 33580222, DOI: 10.1038/s41571-021-00473-5.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsSelection of patientsPD-L1L1 antibodyImmunohistochemistry assaysPD-L1 immunohistochemistry assaysOutcomes of patientsBiomarkers of responseCompanion diagnostic assayTypes of cancerPD-1Clinical outcomesSelection biomarkerProspective comparisonClinical challengeNew therapiesFuture treatmentPatientsSolid tumorsClinical useSpecific agentsInter-assay variabilityBiomarkersCurrent roleDiagnostic assays
2020
Biomarkers in Precision Cancer Immunotherapy: Promise and Challenges.
McKean WB, Moser JC, Rimm D, Hu-Lieskovan S. Biomarkers in Precision Cancer Immunotherapy: Promise and Challenges. American Society Of Clinical Oncology Educational Book 2020, 40: e275-e291. PMID: 32453632, DOI: 10.1200/edbk_280571.Peer-Reviewed Original ResearchConceptsHost immune defectsPrecision cancer immunotherapyHealth care burdenCurrent treatment modalitiesSignificant side effectsSustained remissionClinical responseCheckpoint inhibitionImmune defectsRefractory malignanciesCancer immunotherapeuticsClinical benefitPatient survivalCancer immunotherapyPredictive biomarkersTreatment modalitiesCare burdenPatient responseSide effectsTrial designTumor parenchymaClinical useBiomarker developmentBiomarkersMultiple biomarkers
2011
Optimal tumor sampling for immunostaining of biomarkers in breast carcinoma
Tolles J, Bai Y, Baquero M, Harris LN, Rimm DL, Molinaro AM. Optimal tumor sampling for immunostaining of biomarkers in breast carcinoma. Breast Cancer Research 2011, 13: r51. PMID: 21592345, PMCID: PMC3218938, DOI: 10.1186/bcr2882.Peer-Reviewed Original ResearchConceptsWhole tissue sectionsBreast carcinomaEstrogen receptorBiomarker expressionTumor biomarker expressionAmount of tumorTissue sectionsEvidence-based standardsHeterogeneous markersTherapeutic responseHER-2Optimal tumorBreast biopsyBreast tumorsClinical implicationsMAP-tauQuantitative immunofluorescenceClinical useLevel of expressionCarcinomaImmunostaining assaysBiomarkersTumorsTissue samplesBiomarker heterogeneity
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply